Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Sargramostim for Metastatic Melanoma to the Lung
NCT00005610Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2000
- Primary completion
- Jun 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in melanoma, sponsored by Cancer and Leukemia Group B. Primary endpoints: Progression-Free Survival at 2 months and Median Overall Survival at 1.5 years. Started Sep 2000; status: completed.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00005610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005610.